The First Regulatory T (Treg) Cell-Based Immunotherapy

The U.S. Food and Drug Administration (FDA) has approved Tregzi, the first regulatory T (Treg) cell-based immunotherapy designed to reduce the risk of chronic graft-versus-host disease (GVHD) in adults with certain blood cancers undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

The approval marks a significant milestone in cellular immunotherapy, introducing a novel approach that seeks not only to treat cancer but also to prevent one of the most serious long-term complications associated with stem cell transplantation.

Addressing a Major Challenge in Stem Cell Transplantation

Allogeneic hematopoietic stem cell transplantation remains a potentially curative treatment for patients with high-risk blood cancers, including acute leukemia and myelodysplastic syndrome. However, chronic graft-versus-host disease has long been one of the greatest barriers to successful long-term outcomes.

GVHD occurs when transplanted donor immune cells recognize the recipient’s tissues as foreign and begin attacking healthy organs. The condition can affect the skin, liver, lungs, gastrointestinal tract, eyes, and other organs, leading to significant illness, disability, and even death.

Rather than relying solely on medications to suppress the immune response after transplantation, Tregzi is designed to help rebuild the patient’s immune system while reducing the likelihood of harmful immune attacks.

First-in-Class Cellular Therapy

Tregzi is a donor-derived cellular immunotherapy manufactured from blood collected from an 8/8 HLA-matched related or unrelated donor.

The therapy contains three distinct cellular components. Hematopoietic stem and progenitor cells (HSPCs), regulatory T cells (Tregs), and conventional T cells (Tcons).

Regulatory T cells play a critical role in maintaining immune tolerance by moderating excessive immune responses. By incorporating these specialized immune cells into the transplant product, the therapy is intended to reduce chronic GVHD while preserving the donor immune system’s ability to combat residual cancer cells.

Clinical Trial Demonstrated Significant Improvement

FDA based its approval on results from the randomized Phase 3 PRECISION-T clinical trial involving 187 adults with high-risk blood cancers.

Patients receiving Tregzi experienced substantially improved chronic GVHD-free survival compared with those receiving conventional stem cell transplantation.

Key findings included that 78% of patients receiving Tregzi remained alive and free of moderate or severe chronic GVHD one year after transplantation and 38.4% of patients receiving standard transplantation achieved the same outcome. In addition, serious chronic GVHD developed in 12.6% of Tregzi recipients compared with 44% of patients receiving standard transplantation.

FDA described the study results as highly persuasive and internally consistent, concluding that the demonstrated clinical benefits outweighed the therapy’s risks.

Safety Profile

The most frequently reported adverse events were infections, consistent with those commonly observed following stem cell transplantation. Notably, investigators reported no severe infusion reactions and no cases of graft failure during the study period.

The application received both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) Designation, reflecting the therapy’s potential to address a serious unmet medical need. FDA approved Tregzi for Orca Biosystems, Inc.

MDP Perspective

Tregzi represents another important milestone in the continuing evolution of cell and gene therapies. While many recent cellular immunotherapies have focused on directly targeting cancer cells, such as CAR-T therapies, this approval takes a different approach by engineering the immune environment surrounding stem cell transplantation.

From a regulatory perspective, products like Tregzi also illustrate the increasing complexity of biologic manufacturing. Unlike traditional pharmaceuticals, cellular therapies require sophisticated donor selection, cell collection, purification, manufacturing, characterization, and chain-of-identity controls to ensure that each patient receives the correct living cell product while maintaining product quality and consistency.

The approval further highlights FDA’s continued support for innovative regenerative medicine through programs such as the Regenerative Medicine Advanced Therapy (RMAT) designation. As more individualized and donor-derived cellular therapies enter clinical practice, manufacturers will face increasing regulatory expectations surrounding manufacturing controls, analytical characterization, potency testing, and long-term product safety.

For regulatory professionals, Tregzi demonstrates how advances in immunology are increasingly being paired with equally sophisticated regulatory and manufacturing strategies, expanding the role of advanced biologics in treating complex diseases while reducing treatment-related complications.